Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,531 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26887
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
· Eur Urol · 2017 · PMID 27751729 · validated civic_curation pubmed
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
· PLoS One · 2014 · PMID 24647522 · validated civic_curation pubmed
Pembrolizumab for the treatment of non-small-cell lung cancer.
· N Engl J Med · 2015 · PMID 25891174 · validated civic_curation pubmed
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted
· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
· J Clin Oncol · 2018 · PMID 29182496 · validated civic_curation pubmed
EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.
· J Investig Med · 2017 · PMID 27664271 · validated civic_curation pubmed
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
· J Clin Oncol · 2018 · PMID 29320312 · validated

Showing 176–200 of 916 publications

← Previous
1
…
7
8
9
…
37
Next →

civic_curation

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

· Cancer Discov · 2018 · PMID 29773717 · validated civic_curation pubmed

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

· J Clin Oncol · 2018 · PMID 29072975 · validated civic_curation pubmed

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

· Lancet Oncol · 2011 · PMID 21783417 · validated civic_curation pubmed

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

· Lancet Oncol · 2018 · PMID 30413378 · validated civic_curation pubmed

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

· Ann Oncol · 2019 · PMID 31086949 · validated civic_curation pubmed

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

· Cancer Discov · 2019 · PMID 31575541 · validated civic_curation pubmed

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

· N Engl J Med · 2020 · PMID 32846060 · validated civic_curation pubmed

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

· Gastroenterology · 2012 · PMID 22705007 · validated civic_curation pubmed

Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.

· Future Oncol · 2015 · PMID 26169997 · validated civic_curation pubmed

TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

· Am J Surg Pathol · 2016 · PMID 26975036 · validated civic_curation pubmed

Integrative clinical and molecular characterization of translocation renal cell carcinoma.

· Cell Rep · 2022 · PMID 34986355 · validated civic_curation pubmed

A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas.

· Am J Surg Pathol · 2010 · PMID 20588178 · validated civic_curation pubmed

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

· N Engl J Med · 2023 · PMID 37611121 · validated civic_curation pubmed

Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.

· Nat Commun · 2019 · PMID 30664630 · validated civic_curation pubmed

NUT carcinoma in children and adults: A multicenter retrospective study.

· Pediatr Blood Cancer · 2017 · PMID 28643357 · validated civic_curation pubmed